Research Topics
Species | K I AtagaSummaryAffiliation: University of North Carolina Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Pulmonary hypertension in sickle cell diseaseKenneth I Ataga
Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
Am J Med 117:665-9. 2004..We sought to determine the prevalence of pulmonary hypertension in adult patients with sickle cell disease and to identify factors associated with this life-threatening complication...
Association of coagulation activation with clinical complications in sickle cell diseaseKenneth I Ataga
Division of Hematology Oncology, University of North Carolina, Chapel Hill, North Carolina, United States of America
PLoS ONE 7:e29786. 2012..We sought to evaluate the association of markers of coagulation and platelet activation with specific clinical complications and laboratory variables in patients with SCD...
Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell diseaseKenneth I Ataga
Comprehensive Sickle Cell Program Division of Hematology Oncology Department of Biochemistry and Biophysics Department of Biostatistics Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599 7305, USA
Br J Haematol 152:485-91. 2011..By inducing endothelial dysfunction, sFLT-1 may contribute to the pathogenesis of SCD-associated PHT, although this effect does not appear to be independent of haemolysis...- Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1Kenneth I Ataga
Comprehensive Sickle Cell Program, University of North Carolina, Chapel Hill, NC, USA
Eur J Haematol 85:257-63. 2010..The purpose of this exploratory study was to determine the relationship between albuminuria and both clinical and laboratory variables in SCD... - Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemiaKenneth I Ataga
Division of Hematology Oncology, University of North Carolina at Chapel Hill, Room 3149, Physicians Office Building, CB 7305, Chapel Hill, NC 27599 7305, USA
Expert Opin Investig Drugs 18:231-9. 2009.... - Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemiaKenneth I Ataga
Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB no 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27599 7305, USA
Blood 111:3991-7. 2008..This study is registered at http://clinicaltrials.gov as NCT00040677... - Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertensionKenneth I Ataga
Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Bldg Chapel Hill, NC 27599 7305, USA
Haematologica 93:20-6. 2008..Pulmonary hypertension (PHT) is common in sickle cell disease (SCD). The purpose of this study was to determine whether markers of coagulation activation and inflammation are associated with PHT in SCD... - Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulabilityKenneth I Ataga
Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
Br J Haematol 139:3-13. 2007.... - Dose-escalation study of ICA-17043 in patients with sickle cell diseaseKenneth I Ataga
Division of Hematology Oncology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
Pharmacotherapy 26:1557-64. 2006..To determine the dose tolerance, safety, and pharmacokinetics of a single oral dose of ICA-17043 in patients with sickle cell disease... - Pulmonary hypertension in patients with sickle cell disease: a longitudinal studyKenneth I Ataga
Division of Hematology Oncology and Comprehensive Sickle Cell Program, University of North Carolina, Chapel Hill, NC, USA
Br J Haematol 134:109-15. 2006.... - Renal abnormalities in sickle cell diseaseK I Ataga
Division of Hematology Oncology, Department of Medicine, UNC Comprehensive Sickle Cell Program and General Clinical Research Center, University of North Carolina, Chapel Hill, North Carolina, USA
Am J Hematol 63:205-11. 2000..Finally, progression of sickle cell nephropathy to ESRD may be slowed by adequate control of hypertension and proteinuria. However, the prevention of the renal complications of SCD will require a cure for this genetic disorder... - Hypercoagulability in sickle cell disease: a curious paradoxKenneth I Ataga
Division of Hematology Oncology, Department of Medicine, University of North Carolina Comprehensive Sickle Cell Program, Chapel Hill, North Carolina 27599 7305, USA
Am J Med 115:721-8. 2003..This review discusses hypercoagulability in the various forms of sickle cell disease, including homozygous sickle cell anemia, hemoglobin SC disease, hemoglobin SD disease, and sickle cell-beta-thalassemia... - Renal cell carcinomaP A Godley
University of North Carolina at Chapel Hill, Division of Hematology Oncology and the Lineberger Comprehensive Cancer Center, Chapel Hill 27599 7305, USA
Curr Opin Oncol 12:260-4. 2000..In addition, patients with deletion (8p)/-8, +12, and +20 appear to have a worse prognosis... - Placenta growth factor in sickle cell disease: association with hemolysis and inflammationJulia E Brittain
Department of Biochemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
Blood 115:2014-20. 2010..Prospective studies are required to conclusively define the contribution of PlGF to the pathogenesis of PHT and other hemolytic complications in SCD... - Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trialE P Orringer
School of Medicine, University of North Carolina at Chapel Hill, Room 125, MacNider Bldg, CB7000, Chapel Hill, NC 27599 7000, USA
JAMA 286:2099-106. 2001..Purified poloxamer 188 may increase tissue oxygenation and thereby reduce inflammation, pain, and the overall duration of such painful episodes in patients with SCD... - Delayed hemolytic transfusion reaction in sickle cell diseaseLeslie P Scheunemann
Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
Am J Med Sci 339:266-9. 2010..It is important that delayed hemolytic transfusion reactions be included in the differential diagnosis of acute pain episodes following a red blood cell transfusion in a patient with sickle cell disease... - Hypercoagulability in sickle cell disease and beta-thalassemiaSylvia T Singer
Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA
Curr Mol Med 8:639-45. 2008..Furthermore, adequately controlled studies using anticoagulants and antiplatelet agents are warranted to define the role of hypercoagulability in specific complications of these diseases... - Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammationSheritha P Lee
Department of Pharmacology, University of North Carolina, CB#7365, Chapel Hill, NC 27599-7365, USA
Arterioscler Thromb Vasc Biol 26:1626-31. 2006..The participation of sCD40L in SCA plasma-induced production of B cells, tissue factor, and ICAM-1 suggests that CD40L may contribute to the chronic inflammation and increased thrombotic activity known to occur in SCA... - Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell diseaseAllison E Ashley-Koch
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Blood 111:5721-6. 2008..These findings may offer new promise for identifying patients at risk for pHTN, developing new therapeutic targets, and reducing the occurrence of this life-threatening SCD complication... - Mechanism of CD47-induced alpha4beta1 integrin activation and adhesion in sickle reticulocytesJulia E Brittain
Department of Pharmacology, University of North Carolina at Chapel Hill, 27599 7365, USA
J Biol Chem 279:42393-402. 2004..These studies therefore identify the alpha4beta1 integrin on SS RBCs as a CD47-activated receptor for TSP, VCAM-1, and plasma fibronectin, revealing novel binding characteristics of this integrin... - Phase I study of eptifibatide in patients with sickle cell anaemiaSheritha P Lee
Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7365, USA
Br J Haematol 139:612-20. 2007..Based on these phase I results, eptifibatide may benefit SCA patients by inhibiting platelet aggregation, decreasing sCD40L levels and favourably altering plasma levels of inflammatory mediators... - Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesionPatrick C Hines
Department of Pharmacology, University of North Carolina at Chapel Hill, 27599, USA
Blood 101:3281-7. 2003.... - Genetic polymorphisms associated with priapism in sickle cell diseaseLaine Elliott
Department of Medicine, Duke University and VA Medical Centers, Durham, NC 27710, USA
Br J Haematol 137:262-7. 2007..Our data suggest that genes involved in the TGFbeta pathway, coagulation, cell adhesion and cell hydration pathways may be important in risk for priapism... - Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LUMeghan M Murphy
Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Blood 105:3322-9. 2005..These results demonstrate that Epac-induced Rap1 activation in SS RBCs promotes BCAM/LU-mediated adhesion to laminin. Thus, Epac-mediated Rap1 activation may represent an important signaling pathway for promoting SS RBC adhesion... - Fibronectin bridges monocytes and reticulocytes via integrin alpha4beta1Julia E Brittain
Departments of Pharmacology, and Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, NC, USA
Br J Haematol 141:872-81. 2008....
Research Grants
- DISORDERED BLOOD COAGULATION IN SICKLE CELL DISEASEKenneth Ataga; Fiscal Year: 2006..e., is the "hypercoagulability" observed in patients with SCD a primary cause of the vasoocclusion or is it simply a secondary event that is observed in this clinical setting. ..
- COAGULATION ACTIVATION IN SICKLE CELL DISEASEKenneth Ataga; Fiscal Year: 2009..abstract_text> ..
- COAGULATION ACTIVATION IN SICKLE CELL DISEASEKenneth I Ataga; Fiscal Year: 2010..abstract_text> ..